Genentech allies with a metagenomics upstart in New York on a discovery deal jam packed with biobucks
Genentech has turned to a biotech startup in New York for its latest discovery pact.
The big Roche group is lending its marquee status to little Lodo Therapeutics, which is plumbing microbial DNA sequence information contained in soil for fresh leads on novel therapeutics. Based in the Alexandria Center for Life Science in midtown Manhattan, the company launched in early 2016 with a $17 million Series A and a quest to explore the information they can find encoded in bacterial genomes — a break from culturing known strains of bacteria, which has some extreme limitations.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.